Acumen Pharmaceuticals (ABOS) insider plans 15,085-share Rule 144 sale

Rhea-AI Filing Summary

Acumen Pharmaceuticals insider plans additional stock sale under Rule 144. The notice covers up to 15,085 shares of common stock to be sold through Merrill Lynch on or about 01/27/2026 on the NASDAQ market, with an aggregate market value of $45,262.48. These shares were acquired the same day via a broker-assisted cashless exercise of employee stock options.

The filing also lists prior sales of Acumen Pharmaceuticals common stock during January 2026 by Derek Meisner, including multiple transactions ranging from 1,054 to 36,911 shares. Shares of Acumen Pharmaceuticals outstanding were 60,573,425 at the time referenced, providing context for the size of the planned and recent sales.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	15085	45262.48	60573425	01/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/27/2026	Exercise of employee stock options	Acumen Pharmaceuticals, Inc.			15085	01/27/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7838.00
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	10898	21437.56
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	11770	23414.63
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/08/2026	36911	67244.23
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/09/2026	5200	9169.00
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/12/2026	8548	14658.02
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/21/2026	2247	4063.33
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/22/2026	1054	1939.36
Derek Meisner 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/23/2026	5633	10492.83

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for ABOS disclose?

The Form 144 discloses a planned sale of up to 15,085 shares of Acumen Pharmaceuticals common stock on NASDAQ, with an aggregate market value of $45,262.48 at the time of the notice.

How were the 15,085 ABOS shares to be sold acquired?

The 15,085 Acumen Pharmaceuticals shares were acquired on 01/27/2026 through an exercise of employee stock options via a broker-assisted cashless exercise.

Who is selling ABOS shares in this Form 144?

The Form 144 lists Derek Meisner as the person for whose account Acumen Pharmaceuticals common stock is to be sold and as the seller in prior January 2026 transactions.

What recent ABOS stock sales are reported for the past 3 months?

The filing lists multiple January 2026 sales of Acumen Pharmaceuticals common stock by Derek Meisner, with individual transactions ranging from 1,054 to 36,911 shares and corresponding gross proceeds.

How many ABOS shares were outstanding in this Form 144?

The Form 144 states that 60,573,425 shares of Acumen Pharmaceuticals common stock were outstanding, providing a baseline for evaluating the size of the planned sale.

Which broker is handling the planned ABOS share sale?

The planned sale of Acumen Pharmaceuticals common stock is to be executed through Merrill Lynch, at its New York office listed in the filing.